{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:36:38Z","timestamp":1791488198610,"version":"4.3.4"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-007122"],"award-info":[{"award-number":["INV-007122"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["1134989"],"award-info":[{"award-number":["1134989"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1134989"],"award-info":[{"award-number":["1134989"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["200909"],"award-info":[{"award-number":["200909"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1104975"],"award-info":[{"award-number":["1104975"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-009390"],"award-info":[{"award-number":["INV-009390"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012155","name":"Channel 7 Telethon Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In 2017, an estimated 14 million cases of\n                      <jats:italic>Plasmodium vivax<\/jats:italic>\n                      malaria were reported from Asia, Central and South America, and the Horn of Africa. The clinical burden of vivax malaria is largely driven by its ability to form dormant liver stages (hypnozoites) that can reactivate to cause recurrent episodes of malaria. Elimination of both the blood and liver stages of the parasites (\u201cradical cure\u201d) is required to achieve a sustained clinical response and prevent ongoing transmission of the parasite. Novel treatment options and point-of-care diagnostics are now available to ensure that radical cure can be administered safely and effectively. We quantified the global economic cost of vivax malaria and estimated the potential cost benefit of a policy of radical cure after testing patients for glucose-6-phosphate dehydrogenase (G6PD) deficiency.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>Estimates of the healthcare provider and household costs due to vivax malaria were collated and combined with national case estimates for 44 endemic countries in 2017. These provider and household costs were compared with those that would be incurred under 2 scenarios for radical cure following G6PD screening: (1) complete adherence following daily supervised primaquine therapy and (2) unsupervised treatment with an assumed 40% effectiveness. A probabilistic sensitivity analysis generated credible intervals (CrIs) for the estimates. Globally, the annual cost of vivax malaria was US$359 million (95% CrI: US$222 to 563 million), attributable to 14.2 million cases of vivax malaria in 2017. From a societal perspective, adopting a policy of G6PD deficiency screening and supervision of primaquine to all eligible patients would prevent 6.1 million cases and reduce the global cost of vivax malaria to US$266 million (95% CrI: US$161 to 415 million), although healthcare provider costs would increase by US$39 million. If perfect adherence could be achieved with a single visit, then the global cost would fall further to US$225 million, equivalent to $135 million in cost savings from the baseline global costs. A policy of unsupervised primaquine reduced the cost to US$342 million (95% CrI: US$209 to 532 million) while preventing 2.1 million cases. Limitations of the study include partial availability of country-level cost data and parameter uncertainty for the proportion of patients prescribed primaquine, patient adherence to a full course of primaquine, and effectiveness of primaquine when unsupervised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our modelling study highlights a substantial global economic burden of vivax malaria that could be reduced through investment in safe and effective radical cure achieved by routine screening for G6PD deficiency and supervision of treatment. Novel, low-cost interventions for improving adherence to primaquine to ensure effective radical cure and widespread access to screening for G6PD deficiency will be critical to achieving the timely global elimination of\n                      <jats:italic>P<\/jats:italic>\n                      .\n                      <jats:italic>vivax<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1003614","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T13:37:52Z","timestamp":1622554672000},"page":"e1003614","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3321-8706","authenticated-orcid":true,"given":"Angela","family":"Devine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2401-2615","authenticated-orcid":true,"given":"Katherine E.","family":"Battle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5324-8307","authenticated-orcid":true,"given":"Niamh","family":"Meagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind E.","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4613-3672","authenticated-orcid":true,"given":"Saber","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Gething","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2660-2013","authenticated-orcid":true,"given":"Julie A.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2000-2874","authenticated-orcid":true,"given":"Ric N.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0237-1070","authenticated-orcid":true,"given":"Yoel","family":"Lubell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"issue":"7572","key":"pmed.1003614.ref001","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nature15535","article-title":"The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015","volume":"526","author":"S Bhatt","year":"2015","journal-title":"Nature"},{"issue":"10195","key":"pmed.1003614.ref002","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0140-6736(19)31096-7","article-title":"Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000\u201317: a spatial and temporal modelling study","volume":"394","author":"KE Battle","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"pmed.1003614.ref003","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.pt.2020.03.009","article-title":"Plasmodium vivax in the Era of the Shrinking P. falciparum Map","volume":"36","author":"RN Price","year":"2020","journal-title":"Trends Parasitol"},{"issue":"1","key":"pmed.1003614.ref004","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12916-020-1497-0","article-title":"The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study.","volume":"18","author":"S Dini","year":"2020","journal-title":"BMC Med."},{"issue":"1","key":"pmed.1003614.ref005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1128\/CMR.00074-12","article-title":"Evidence and implications of mortality associated with acute Plasmodium vivax malaria","volume":"26","author":"JK Baird","year":"2013","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"pmed.1003614.ref006","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/infdis\/jit261","article-title":"Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax","volume":"208","author":"NM Douglas","year":"2013","journal-title":"J Infect Dis"},{"key":"pmed.1003614.ref007","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12916-014-0217-z","article-title":"Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia","volume":"12","author":"NM Douglas","year":"2014","journal-title":"BMC Med"},{"issue":"12","key":"pmed.1003614.ref008","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1086\/599041","article-title":"Vivax Malaria: A Major Cause of Morbidity in Early Infancy","volume":"48","author":"JR Poespoprodjo","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pmed.1003614.ref009","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12916-017-0877-6","article-title":"Influence of the number and timing of malaria episodes during pregnancy on prematurity and small-for-gestational-age in an area of low transmission","volume":"15","author":"KA Moore","year":"2017","journal-title":"BMC Med."},{"key":"pmed.1003614.ref010","volume-title":"Guidelines for the Treatment of Malaria","author":"World Health Organisation","year":"2015"},{"issue":"8","key":"pmed.1003614.ref011","doi-asserted-by":"crossref","first-page":"e1002379","DOI":"10.1371\/journal.pmed.1002379","article-title":"Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study","volume":"14","author":"NM Douglas","year":"2017","journal-title":"PLoS Med"},{"issue":"3","key":"pmed.1003614.ref012","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0035-9203(03)00041-5","article-title":"Compliance with 14-day primaquine therapy for radical cure of vivax malaria\u2014a randomized placebo-controlled trial comparing unsupervised with supervised treatment","volume":"98","author":"T Leslie","year":"2004","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pmed.1003614.ref013","article-title":"Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria","author":"CS Chu","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"10202","key":"pmed.1003614.ref014","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(19)31285-1","article-title":"Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial","volume":"394","author":"WRJ Taylor","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"pmed.1003614.ref015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1710775","article-title":"Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria","volume":"380","author":"MVG Lacerda","year":"2019","journal-title":"N Engl J Med"},{"key":"pmed.1003614.ref016","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/1475-2875-13-418","article-title":"Primaquine: the risks and the benefits","volume":"13","author":"EA Ashley","year":"2014","journal-title":"Malar J"},{"issue":"11","key":"pmed.1003614.ref017","doi-asserted-by":"crossref","first-page":"e1001339","DOI":"10.1371\/journal.pmed.1001339","article-title":"G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map","volume":"9","author":"RE Howes","year":"2012","journal-title":"PLoS Med."},{"issue":"1","key":"pmed.1003614.ref018","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12936-017-1784-1","article-title":"Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group","volume":"16","author":"K Thriemer","year":"2017","journal-title":"Malar J."},{"issue":"12","key":"pmed.1003614.ref019","doi-asserted-by":"crossref","first-page":"828","DOI":"10.2471\/BLT.18.226688","article-title":"Provider and household costs of Plasmodium vivax malaria episodes: a multicountry comparative analysis of primary trial data","volume":"97","author":"A Devine","year":"2019","journal-title":"Bull World Health Organ"},{"issue":"12","key":"pmed.1003614.ref020","doi-asserted-by":"crossref","first-page":"e1002992","DOI":"10.1371\/journal.pmed.1002992","article-title":"Performance of the Access Bio\/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis","volume":"16","author":"B Ley","year":"2019","journal-title":"PLoS Med"},{"key":"pmed.1003614.ref021","unstructured":"USAID. The DHS Program: USAID; 2017 [cited 2017 July 28]. Available from: http:\/\/www.dhsprogram.com\/."},{"key":"pmed.1003614.ref022","unstructured":"World Health Organization. World malaria report 2018. Geneva, Switzerland: World Health Organization; 2018 [cited 2018 November 26]. Available from: https:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2018\/en\/."},{"issue":"9","key":"pmed.1003614.ref023","doi-asserted-by":"crossref","first-page":"e1814","DOI":"10.1371\/journal.pntd.0001814","article-title":"A Long Neglected World Malaria Map: Plasmodium vivax Endemicity in 2010","volume":"6","author":"PW Gething","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"pmed.1003614.ref024","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1475-2875-6-131","article-title":"Standardizing estimates of the Plasmodium falciparum parasite rate","volume":"6","author":"DL Smith","year":"2007","journal-title":"Malar J"},{"issue":"1","key":"pmed.1003614.ref025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12936-018-2190-z","article-title":"Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms","volume":"17","author":"JK Baird","year":"2018","journal-title":"Malar J"},{"key":"pmed.1003614.ref026","unstructured":"The World Bank. Inflation, GDP deflator (annual %): The World Bank; 2009\u20132017 [updated 2020 October 15; cited 2020 December 9]. Available from: https:\/\/data.worldbank.org\/indicator\/NY.GDP.DEFL.KD.ZG."},{"key":"pmed.1003614.ref027","unstructured":"The World Bank. Official exchange rate (LCU per US$, period average): The World Bank; 2017 [updated 2020 October 15; cited 2020 Dec 9]. Available from: https:\/\/data.worldbank.org\/indicator\/PA.NUS.FCRF."},{"key":"pmed.1003614.ref028","unstructured":"World Health Organisation. WHO-CHOICE unit cost estimates for service delivery. Geneva, Switzerland; 2011 [cited 2016 February 2]. Available from: http:\/\/www.who.int\/choice\/cost-effectiveness\/inputs\/health_service\/en\/."},{"key":"pmed.1003614.ref029","unstructured":"Management Sciences for Health. International Medical Products Price Guide, 2015 Edition. Arlington, VA: Management Sciences for Health; 2017 [cited 2017 October 26]. Available from: http:\/\/mshpriceguide.org\/en\/home\/."},{"key":"pmed.1003614.ref030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/1475-2875-13-481","article-title":"Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900.","volume":"13","author":"BA Rahimi","year":"2014","journal-title":"Malar J"},{"issue":"3","key":"pmed.1003614.ref031","doi-asserted-by":"crossref","first-page":"e0004494","DOI":"10.1371\/journal.pntd.0004494","article-title":"Costs Associated with Malaria in Pregnancy in the Brazilian Amazon, a Low Endemic Area Where Plasmodium vivax Predominates","volume":"10","author":"C Botto-Menezes","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pmed.1003614.ref032","doi-asserted-by":"crossref","first-page":"e1002815","DOI":"10.1371\/journal.pmed.1002815","article-title":"Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study","volume":"16","author":"E Kenangalem","year":"2019","journal-title":"PLoS Med."},{"issue":"1","key":"pmed.1003614.ref033","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12936-016-1140-x","article-title":"Cost-effectiveness analysis of rapid diagnostic tests for G6PD deficiency in patients with Plasmodium vivax malaria in the Brazilian Amazon","volume":"15","author":"HM Peixoto","year":"2016","journal-title":"Malar J"},{"key":"pmed.1003614.ref034","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/1475-2875-11-390","article-title":"Cost-effectiveness of diagnostic for malaria in Extra-Amazon Region, Brazil","volume":"11","author":"MR de Oliveira","year":"2012","journal-title":"Malar J"},{"key":"pmed.1003614.ref035","unstructured":"UNdata. Per capita GDP at current prices\u2014US dollars New York, NY: United Nations; 2017 [updated 2020\/02\/10; cited 2020 December 9]. Available from: http:\/\/data.un.org\/Data.aspx?q=GDP+per+capita&d=SNAAMA&f=grID:101;currID:USD;pcFlag:true;crID:232,408,410,807,862;yr:2017&c=2,3,5,6&s=_crEngNameOrderBy:asc,yr:desc&v=1."},{"key":"pmed.1003614.ref036","unstructured":"The World Bank. GDP per capita (current US$) The World Bank; 2017 [updated 2020 October 15; cited 2020 Dec 9]. Available from: http:\/\/http:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD."},{"key":"pmed.1003614.ref037","first-page":"Cd012656","article-title":"Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax","volume":"8","author":"R Milligan","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"pmed.1003614.ref038","doi-asserted-by":"crossref","first-page":"e84555","DOI":"10.1371\/journal.pone.0084555","article-title":"How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs","volume":"9","author":"K Bruxvoort","year":"2014","journal-title":"PLoS ONE."},{"key":"pmed.1003614.ref039","article-title":"Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis","author":"RJ Commons","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"pmed.1003614.ref040","article-title":"Key Knowledge Gaps for Plasmodium vivax Control and Elimination","author":"Q Bassat","year":"2016","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"pmed.1003614.ref041","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-3156.2006.01590.x","article-title":"The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania","volume":"11","author":"JA Mulligan","year":"2006","journal-title":"Trop Med Int Health"},{"key":"pmed.1003614.ref042","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1475-2875-7-4","article-title":"The costs of introducing artemisinin-based combination therapy: evidence from district-wide implementation in rural Tanzania","volume":"7","author":"JD Njau","year":"2008","journal-title":"Malar J"},{"issue":"1","key":"pmed.1003614.ref043","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1038\/s41467-019-13412-x","article-title":"Resolving the cause of recurrent Plasmodium vivax malaria probabilistically","volume":"10","author":"AR Taylor","journal-title":"Nat Commun"},{"issue":"3","key":"pmed.1003614.ref044","doi-asserted-by":"crossref","first-page":"e0003595","DOI":"10.1371\/journal.pntd.0003595","article-title":"Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo","volume":"9","author":"AI Adekunle","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pmed.1003614.ref045","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.4269\/ajtmh.2010.09-0521","article-title":"Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon","volume":"82","author":"KP Grietens","year":"2010","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"pmed.1003614.ref046","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12936-018-2380-8","article-title":"Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group","volume":"17","author":"K Thriemer","year":"2018","journal-title":"Malar J"},{"issue":"1","key":"pmed.1003614.ref047","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1038\/s41467-018-05860-8","article-title":"Mathematical modelling of the impact of expanding levels of malaria control interventions on Plasmodium vivax","volume":"9","author":"MT White","year":"2018","journal-title":"Nat Commun"},{"key":"pmed.1003614.ref048","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/B978-0-12-397900-1.00005-0","article-title":"Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria","volume":"80","author":"NM Douglas","year":"2012","journal-title":"Adv Parasitol"},{"key":"pmed.1003614.ref049","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/1475-2875-8-230","article-title":"Malaria is associated with poor school performance in an endemic area of the Brazilian Amazon.","volume":"8","author":"S Vitor-Silva","year":"2009","journal-title":"Malar J."},{"issue":"2","key":"pmed.1003614.ref050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1257\/app.2.2.46","article-title":"Malaria Eradication and Educational Attainment: Evidence from Paraguay and Sri Lanka","volume":"2","author":"AM Lucas","year":"2010","journal-title":"Am Econ J Appl Econ"},{"issue":"3","key":"pmed.1003614.ref051","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1086\/669261","article-title":"The Impact of Malaria Eradication on Fertility","volume":"61","author":"AM Lucas","year":"2013","journal-title":"Econ Dev Cult Change"},{"issue":"2","key":"pmed.1003614.ref052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1257\/app.2.2.1","article-title":"Malaria Eradication in the Americas: A Retrospective Analysis of Childhood Exposure","volume":"2","author":"H. Bleakley","year":"2010","journal-title":"Am Econ J Appl Econ"},{"key":"pmed.1003614.ref053","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12936-015-0706-3","article-title":"Defining the relationship between Plasmodium vivax parasite rate and clinical disease","volume":"14","author":"KE Battle","year":"2015","journal-title":"Malar J"},{"issue":"1","key":"pmed.1003614.ref054","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4269\/ajtmh.18-0612","article-title":"Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patient","volume":"100","author":"S Pal","year":"2019","journal-title":"Am J Trop Med Hyg"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T13:40:59Z","timestamp":1622554859000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003614"}},"subtitle":[],"editor":[{"given":"Sydney","family":"Rosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":54,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003614","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}